Senseera Health Overview
Senseera’s technology ushers a new generation of liquid biopsy blood tests providing unparalleled information about disease processes in the patient’s internal organs and immune system with a single blood test. Senseera’s mission is to transform disease diagnosis and treatment and to enhance development of new therapeutics. The company uses molecular biology, next generation sequencing, and advanced computational analysis to extract rich epigenetic information encoded in chromatin fragments circulating in the blood and transform it into concrete clinical information. Its cfChIP-seq technology uses the natural biological marking of chromatin to specifically enrich informative DNA fragments from active regions in the genome. Since the active part of the genome is relatively small we bypass the need for biased preselection of specific genes or markers. This unbiased approach increases the disease detection sensitivity and specificity and allows testing for many diseases for a significantly reduced cost, thus setting the stage for an extremely accurate and affordable human health screening. Senseera first line of products is focused in developing an accurate, sensitive, and affordable blood test for early detection and monitoring of cancer. The company is also working closely with pharma companies to improve clinical trials monitoring, patients selection and evaluation of drug efficacy.
Cumulative Funding Raised Over Time ($)
$7.1MJan 2025
$7.1MNov 2023
Latest News
growth-positive
Israeli biotech Senseera raises $7.1 million Seed round for liquid biopsy platform
Senseera, a Jerusalem-based biotech company, has secured $7.1 million in Seed funding led by Lightspeed Venture Partners, with contributions from I-Next Capital and the Lowy Medical Research Institute. The funds will be used to advance Senseeras GEM BIOMARKERS liquid biopsy platform, which aims to enhance diagnostics in oncology, immunology, and liver disease management. The platform uses cfChIP-seq technology to provide biopsy-level precision through a simple blood test, potentially improving diagnosis and management of conditions like liver diseases and cancer. The funding will accelerate clinical development, expand partnerships with global biopharma companies, and support additional clinical trials.
InvestmentPartnersProduct Stage
growth-positive
Assuta's 'RISE with US' launches with six startups looking for international markets | CTech
Assutas innovation arm RISE has launched a program called RISE with US in collaboration with the University City Science Center. The program aims to help startups in the healthcare sector successfully enter international markets. Six companies were selected for the program, focusing on digital health solutions. Assuta has partnered with technology companies such as AWS and NVIDIA, as well as venture capital fund LionBird and law firms Reinhold Cohn & Co. and Naomi Asia & Co. The selected startups will receive mentorship, access to a network of contacts, and clinical mentorship from doctors. The program also provides access to hospitals, insurers, and academic centers in the Philadelphia area. The companies will receive guidance on the development and commercialization of their technologies.
PartnersCustomers
growth-positive
Israel Innovation Authority earmarks $69m for food, medical tech projects
The Israel Innovation Authority has allocated NIS 220 million ($69 million) to establish four new consortiums in the fields of cultivated meat, insect farming, fluid sampling for medical diagnosis, and human-robot interface. The consortiums will bring together industrial companies, research institutions, and startups to jointly develop technologies. This investment represents one of the largest public-sector investments in cultivated meat globally and highlights Israels role as a pioneer in the alternative proteins market. The cultivated meat consortium will be led by Tnuva, a major Israeli food company, while other consortiums will focus on black soldier flies, disease detection, and improving human-robot interaction. The Israel Innovation Authority aims to support groundbreaking technological areas with significant economic impact.
Investment
growth-positive
WATCH: Israeli Researchers Replace Painful Biopsies With Simple Blood Draws United with Israel
Israeli doctors have developed a blood test that can replace invasive and painful biopsies for cancer. The technology, developed by Hebrew University scientists and commercialized by Senseera Health, allows for a simple blood draw instead of a biopsy. This innovation is expected to have a positive impact on the growth of Senseera Health. The key theme of the article is the development of a non-invasive diagnostic tool for cancer. The key issue discussed is the improvement in diagnostic resources for medical professionals. The article does not mention any specific partners, customers, valuation amount, acquisition amount, investment amount, layoffs, or date of the event. Confidence level: 8
Customers
growth-positive
Futuristic Israeli blood test could replace cancer screening in decade: inventor
Hebrew University scientists have developed a blood test that could replace nearly all cancer screenings within a decade. The test can detect not only whether a person has a tumor but also its exact location in the body. It analyzes DNA sequence and epigenetic information to provide detailed insights on genetic activity. The technology has been tested on 1,000 people in Israel and the US and has shown promising results. The test could lead to early detection of cancer and other diseases, potentially saving lives. The research has been published in the peer-reviewed journal, Nature Biotechnology.
Customers
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $7.1M |
| Last funding | $7.1M |
| Stage | Seed |
| Rounds | 3 |
| Investors | 3 |
Team Members
4
Employees: 11-50
Web & Social Links
| Website | senseerahealth.com |
| Careers | Careers page |
Locations
Jerusalem, Israel
Photos & Videos
1 item(s)
Senseera Health Business
Business models
B2B
Product stage
Clinical Trial
Employees
11-50
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyTest Diagnostics & ScreeningTarget Customer
Healthcare & Life SciencesHealthcareLaboratoriesCore Technology
BiologicalsMoleculesTags (10)
disease-managementmolecular-biologylaboratoriesearly-detectiondigital-healthcarebiotechnologymonitoringblood-testcancerdiagnosticsSenseera Health Financials
$7.1M
Total funding
Undisclosed
Capital raised
$7.1M
Last funding
Seed
Funding stage
3
Total rounds
3
Investors
Cumulative Funding Raised Over Time ($)
$7.1MJan 2025
$7.1MNov 2023
Private Equity Funding
Seed
Jan 2025
$7.1M
Lightspeed Venture Partners (Lead)
,
I-Next Capital, Lowy Medical Research Institute
Seed
Nov 2023
Undisclosed
Lightspeed Venture Partners
Non-Equity Funding
GrantEvent
Oct 2021
Undisclosed
Israel Innovation Authority (Lead)
Senseera Health Lifecycle
Cumulative Funding Raised Over Time
$7.1MJan 2025
$7.1MNov 2023
All Events
Seed
Jan 2025
$7.1M
Lightspeed Venture Partners (Lead)
,
I-Next Capital, Lowy Medical Research Institute
Seed
Nov 2023
Undisclosed
Lightspeed Venture Partners
GrantEvent
Oct 2021
Undisclosed
Israel Innovation Authority (Lead)
Senseera Health News
6 articles
growth-positive
Israeli biotech Senseera raises $7.1 million Seed round for liquid biopsy platform
Senseera, a Jerusalem-based biotech company, has secured $7.1 million in Seed funding led by Lightspeed Venture Partners, with contributions from I-Next Capital and the Lowy Medical Research Institute. The funds will be used to advance Senseeras GEM BIOMARKERS liquid biopsy platform, which aims to enhance diagnostics in oncology, immunology, and liver disease management. The platform uses cfChIP-seq technology to provide biopsy-level precision through a simple blood test, potentially improving diagnosis and management of conditions like liver diseases and cancer. The funding will accelerate clinical development, expand partnerships with global biopharma companies, and support additional clinical trials.
InvestmentPartnersProduct Stage
growth-positive
Assuta's 'RISE with US' launches with six startups looking for international markets | CTech
Assutas innovation arm RISE has launched a program called RISE with US in collaboration with the University City Science Center. The program aims to help startups in the healthcare sector successfully enter international markets. Six companies were selected for the program, focusing on digital health solutions. Assuta has partnered with technology companies such as AWS and NVIDIA, as well as venture capital fund LionBird and law firms Reinhold Cohn & Co. and Naomi Asia & Co. The selected startups will receive mentorship, access to a network of contacts, and clinical mentorship from doctors. The program also provides access to hospitals, insurers, and academic centers in the Philadelphia area. The companies will receive guidance on the development and commercialization of their technologies.
PartnersCustomers
growth-positive
Israel Innovation Authority earmarks $69m for food, medical tech projects
The Israel Innovation Authority has allocated NIS 220 million ($69 million) to establish four new consortiums in the fields of cultivated meat, insect farming, fluid sampling for medical diagnosis, and human-robot interface. The consortiums will bring together industrial companies, research institutions, and startups to jointly develop technologies. This investment represents one of the largest public-sector investments in cultivated meat globally and highlights Israels role as a pioneer in the alternative proteins market. The cultivated meat consortium will be led by Tnuva, a major Israeli food company, while other consortiums will focus on black soldier flies, disease detection, and improving human-robot interaction. The Israel Innovation Authority aims to support groundbreaking technological areas with significant economic impact.
Investment
growth-positive
WATCH: Israeli Researchers Replace Painful Biopsies With Simple Blood Draws United with Israel
Israeli doctors have developed a blood test that can replace invasive and painful biopsies for cancer. The technology, developed by Hebrew University scientists and commercialized by Senseera Health, allows for a simple blood draw instead of a biopsy. This innovation is expected to have a positive impact on the growth of Senseera Health. The key theme of the article is the development of a non-invasive diagnostic tool for cancer. The key issue discussed is the improvement in diagnostic resources for medical professionals. The article does not mention any specific partners, customers, valuation amount, acquisition amount, investment amount, layoffs, or date of the event. Confidence level: 8
Customers
growth-positive
Futuristic Israeli blood test could replace cancer screening in decade: inventor
Hebrew University scientists have developed a blood test that could replace nearly all cancer screenings within a decade. The test can detect not only whether a person has a tumor but also its exact location in the body. It analyzes DNA sequence and epigenetic information to provide detailed insights on genetic activity. The technology has been tested on 1,000 people in Israel and the US and has shown promising results. The test could lead to early detection of cancer and other diseases, potentially saving lives. The research has been published in the peer-reviewed journal, Nature Biotechnology.
Customers
growth-positive
ChIP-seq of plasma cell-free nucleosomes identifies gene expression programs of the cells of origin - Nature Biotechnology
The article discusses the availability of data collected in a study, which has been deposited in the European Genome-phenome Archive (EMBL-EBI) and Zenodo repositories. It provides links to various datasets and browser tracks that can be viewed through the UCSC genome browser. The article also mentions the availability of R code for processing cfChIP-seq data on GitHub. Additionally, it references several studies and acknowledges the support from various grants and institutions. The article highlights the contributions of multiple authors and institutions in the research and development of the cfChIP-seq method.
Senseera Health Team
Employee Info
| Employees (range) | 11-50 |
| Exact count | 19 |
| Team members | 4 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 8 classification IDs that could be used for matching.
Senseera Health Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 90/100 |
| Missing | markets, not claimed |
| BI Verification | Yotam Maman |
| Registrar ID | 516240769 |
| Creator | Yanina Wainscheinker |
| Creator email | yanina.wain@gmail.com |
| Last updater | Matan Eblagon |
| Updater email | matane@sncentral.org |
| Last update | 2025-01-07T00:00:00.000Z |
| Created | 2021-02-15T00:00:00.000Z |